Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Linerixibat (GSK2330672) is a highly effective, nonabsorbable ASBT inhibitor (IC50: 42 ± 3 nM). It can lower glucose in an animal model of type 2 diabetes and shows excellent developability properties.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 76.00 | |
2 mg | In stock | $ 119.00 | |
5 mg | In stock | $ 222.00 | |
10 mg | In stock | $ 372.00 | |
25 mg | In stock | $ 629.00 | |
50 mg | In stock | $ 896.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 268.00 |
Description | Linerixibat (GSK2330672) is a highly effective, nonabsorbable ASBT inhibitor (IC50: 42 ± 3 nM). It can lower glucose in an animal model of type 2 diabetes and shows excellent developability properties. |
Targets&IC50 | ASBT:42 ± 3 nM |
Synonyms | GSK2330672, Iinerixibat |
Molecular Weight | 546.68 |
Formula | C28H38N2O7S |
CAS No. | 1345982-69-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 21.5 mg/mL
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Linerixibat 1345982-69-5 Microbiology/Virology HBV type-2 PBC lipid-lowering solubility nonabsorbable Inhibitor Primary diabetes GSK 2330672 Cholangitis inhibit GSK-2330672 GSK2330672 aqueous Biliary ASBT Iinerixibat inhibitor